Research programme: small molecule therapeutic - Eli Lilly/WuXi PharmaTech

Drug Profile

Research programme: small molecule therapeutic - Eli Lilly/WuXi PharmaTech

Latest Information Update: 19 Nov 2015

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; WuXi PharmaTech
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 19 Nov 2015 WuXi PharmaTech and Lilly enter into a strategic collaboration to develop a small molecule for the treatment of cardiovascular disorders in China
  • 10 Nov 2015 Preclinical trials in Cardiovascular disorders in China (PO)
  • 10 Nov 2015 WuXi PharmaTech plans to file an IND in China for Cardiovascular disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top